COR Quote, Financials, Valuation and Earnings

Cardinal Health, Inc. has a net margin of -0.4% compared to Cencora, Inc.'s net margin of 0.71%. Cencora, Inc.'s return on equity of 124.72% beat Cardinal Health, Inc.'s return on equity of --.

Cencora, Inc. has a consensus price target of $384.79, signalling upside risk potential of 14.76%. On the other hand Cardinal Health, Inc. has an analysts' consensus of $214.71 which suggests that it could grow by 7.51%. Given that Cencora, Inc. has higher upside potential than Cardinal Health, Inc., analysts believe Cencora, Inc. is more attractive than Cardinal Health, Inc..

Cencora, Inc. has a beta of 0.632, which suggesting that the stock is 36.802% less volatile than S&P 500. In comparison Cardinal Health, Inc. has a beta of 0.626, suggesting its less volatile than the S&P 500 by 37.423%.

Cencora, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.67%. Cardinal Health, Inc. offers a yield of 1.02% to investors and pays a quarterly dividend of $0.51 per share. Cencora, Inc. pays 27.63% of its earnings as a dividend. Cardinal Health, Inc. pays out 31.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora, Inc. quarterly revenues are $83.7B, which are larger than Cardinal Health, Inc. quarterly revenues of $64B. Cencora, Inc.'s net income of -$333.1M is lower than Cardinal Health, Inc.'s net income of $454M. Notably, Cencora, Inc.'s price-to-earnings ratio is 42.17x while Cardinal Health, Inc.'s PE ratio is 30.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora, Inc. is 0.20x versus 0.21x for Cardinal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of -0.4% compared to Cencora, Inc.'s net margin of 15.47%. Cencora, Inc.'s return on equity of 124.72% beat Globus Medical, Inc.'s return on equity of 10.08%.

Cencora, Inc. has a consensus price target of $384.79, signalling upside risk potential of 14.76%. On the other hand Globus Medical, Inc. has an analysts' consensus of $91.70 which suggests that it could grow by 4.5%. Given that Cencora, Inc. has higher upside potential than Globus Medical, Inc., analysts believe Cencora, Inc. is more attractive than Globus Medical, Inc..

Cencora, Inc. has a beta of 0.632, which suggesting that the stock is 36.802% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 7.046%.

Cencora, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.67%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora, Inc. pays 27.63% of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend. Cencora, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora, Inc. quarterly revenues are $83.7B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Cencora, Inc.'s net income of -$333.1M is lower than Globus Medical, Inc.'s net income of $119M. Notably, Cencora, Inc.'s price-to-earnings ratio is 42.17x while Globus Medical, Inc.'s PE ratio is 28.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora, Inc. is 0.20x versus 4.37x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

McKesson Corp. has a net margin of -0.4% compared to Cencora, Inc.'s net margin of 1.13%. Cencora, Inc.'s return on equity of 124.72% beat McKesson Corp.'s return on equity of --.

Cencora, Inc. has a consensus price target of $384.79, signalling upside risk potential of 14.76%. On the other hand McKesson Corp. has an analysts' consensus of $934.79 which suggests that it could grow by 16.07%. Given that McKesson Corp. has higher upside potential than Cencora, Inc., analysts believe McKesson Corp. is more attractive than Cencora, Inc..

Cencora, Inc. has a beta of 0.632, which suggesting that the stock is 36.802% less volatile than S&P 500. In comparison McKesson Corp. has a beta of 0.382, suggesting its less volatile than the S&P 500 by 61.811%.

Cencora, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.67%. McKesson Corp. offers a yield of 0.38% to investors and pays a quarterly dividend of $0.82 per share. Cencora, Inc. pays 27.63% of its earnings as a dividend. McKesson Corp. pays out 10.69% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora, Inc. quarterly revenues are $83.7B, which are smaller than McKesson Corp. quarterly revenues of $103.2B. Cencora, Inc.'s net income of -$333.1M is lower than McKesson Corp.'s net income of $1.2B. Notably, Cencora, Inc.'s price-to-earnings ratio is 42.17x while McKesson Corp.'s PE ratio is 25.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora, Inc. is 0.20x versus 0.26x for McKesson Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple, Inc. has a net margin of -0.4% compared to Cencora, Inc.'s net margin of -40.74%. Cencora, Inc.'s return on equity of 124.72% beat Pineapple, Inc.'s return on equity of --.

Cencora, Inc. has a consensus price target of $384.79, signalling upside risk potential of 14.76%. On the other hand Pineapple, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cencora, Inc. has higher upside potential than Pineapple, Inc., analysts believe Cencora, Inc. is more attractive than Pineapple, Inc..

Cencora, Inc. has a beta of 0.632, which suggesting that the stock is 36.802% less volatile than S&P 500. In comparison Pineapple, Inc. has a beta of 40.248, suggesting its more volatile than the S&P 500 by 3924.762%.

Cencora, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.67%. Pineapple, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cencora, Inc. pays 27.63% of its earnings as a dividend. Pineapple, Inc. pays out -- of its earnings as a dividend. Cencora, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cencora, Inc. quarterly revenues are $83.7B, which are larger than Pineapple, Inc. quarterly revenues of $2.7K. Cencora, Inc.'s net income of -$333.1M is lower than Pineapple, Inc.'s net income of -$1.1K. Notably, Cencora, Inc.'s price-to-earnings ratio is 42.17x while Pineapple, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cencora, Inc. is 0.20x versus 38.61x for Pineapple, Inc.. Usually stocks with elevated PS ratios are considered overvalued.